GM-CSF stimulates an anti-tumor immune response through priming CD4+ and CD8+ T cells, in part through recruiting and activating dendritic cells, and is currently being investigated for use in pancreatic cancer vaccines (4, 5, 58–60). This evidence concerns the gene CD8A and neoplasm.